-
Polybrene Workflows for Efficient Gene Delivery
2026-09-07
Polybrene (Hexadimethrine Bromide) helps standardize viral attachment and uptake while also supporting difficult lipid-mediated DNA transfection workflows. This guide turns the reagent into a controlled optimization strategy and connects delivery controls with the mitochondrial OGDH biology highlighted in recent research.
-
Natural Compounds Against SARS-CoV-2: Docking Study
2026-09-07
This 2022 Journal of Molecular Modeling study used virtual screening, molecular docking, and molecular dynamics to evaluate natural compounds against the SARS-CoV-2 receptor-binding domain and 3CLpro. Its main contribution is a dual-target computational framework that identifies several vitamin-related molecules as candidates for blocking viral entry and replication, while also highlighting the need for biochemical and cellular validation.
-
LG 101506 in RXR Signaling Research
2026-09-05
Learn how to use LG 101506 as a controlled chemical probe for RXR biology, metabolism regulation, and nuclear receptor assays. This workflow pairs dose-response discipline with orthogonal readouts and a cautious, hypothesis-generating extension to PD-L1 research in triple-negative breast cancer.
-
Proteinase K Workflows for DNA Integrity
2026-09-04
Proteinase K combines broad protein digestion with compatibility across SDS, EDTA, and flexible temperature conditions, making it a practical choice for genomic DNA isolation and enzyme contaminant removal. This guide translates its biochemical strengths—and its distinct role as a control protease in SARS-CoV-2 3CLpro research—into executable workflows and troubleshooting decisions.
-
LRPPRC–Dasatinib Dual OXPHOS Disruption
2026-09-04
The reference study identifies dasatinib as a synergistic partner for LRPPRC inhibition in OXPHOS-dependent cancer models. Its central innovation is a dual-genome mechanism: dasatinib preferentially suppresses nuclear-encoded OXPHOS genes, while LRPPRC inhibition disrupts mitochondrial genome-encoded OXPHOS expression, providing a rationale for combination therapy in LRPPRC-high tumors.
-
3X (DYKDDDDK) Peptide for EMC Workflows
2026-09-03
The 3X (DYKDDDDK) Peptide supports sensitive FLAG-based capture, elution, and detection while preserving options for membrane-complex studies. This practical guide connects FLAG workflows with EMC structural biology, including cryo-EM sample preparation, metal-sensitive assays, and troubleshooting.
-
From P2RX1 Biology to Better Apoptosis Decisions
2026-09-03
A translational framework for connecting P2RX1-driven mitochondrial stress in Ph+ ALL with rapid, decision-ready apoptosis and necrosis measurements using the Annexin V-Cy5/DAPI Apoptosis Kit.
-
Pertussis toxin: Immune Assay Workflow Guide
2026-09-02
Learn how to use Pertussis toxin as a controlled cAMP-pathway perturbation in dendritic-cell, T-cell, and vascular assays. This workflow guide emphasizes dose-finding, orthogonal readouts, storage discipline, and careful interpretation alongside the Dhx9–TH17 research framework.
-
25-Hydroxycholesterol Reprograms TAM Metabolism
2026-09-02
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPKα–STAT6 signaling and ARG1 production in tumor-associated macrophages. Their findings show that targeting this axis can increase T-cell activity and improve anti-PD-1 responses, while also providing a framework for studying metabolic interventions in the tumor microenvironment.
-
LAG-3–TCR Proximity in T Cell Suppression
2026-09-01
A 2025 Cell study shows that LAG-3 inhibition depends less on MHC class II binding alone than on LAG-3 being positioned near the T cell receptor. The work identifies disruption of CD3ε–Lck association as a mechanism and develops an Fc-attenuated LAG-3/TCR bispecific antibody that suppresses pathogenic CD4+ and CD8+ T cells in autoimmune models.
-
Protease Inhibitor Cocktail for Multi-Omics
2026-09-01
A Protease Inhibitor Cocktail can preserve fragile signaling proteins while supporting better interpretation of cancer stem cell multi-omics workflows. This guide explains how an EDTA-free formulation helps align protein extraction with metabolomics, phosphorylation analysis, and assay-specific controls.
-
Verapamil in Hypoxia-Driven Inflammation
2026-08-31
Verapamil ((±)-Verapamil) is a calcium channel blocker and first-generation P-glycoprotein inhibitor used in cardiovascular and drug-transport research. In a urothelial hypoxia model, verapamil attenuated prolonged-hypoxia-associated caspase-1 elevation, supporting its use as a pharmacological perturbation of ROS-linked TXNIP/NLRP3 signaling rather than as proof of selective pathway inhibition.
-
GSK2606414: A Causal Test of PERK in NAFLD
2026-08-31
Explore how GSK2606414, a selective PERK inhibitor, can convert PERK activation from a correlation into a testable mechanism in TMAO-associated fatty liver disease. This guide integrates PERK biology, zebrafish and hepatic-cell evidence, assay design, controls, and translational limitations.
-
Angiotensin 1/2 (5-7): From RAS to Translation
2026-08-30
Angiotensin 1/2 (5-7) is more than a short renin-angiotensin system fragment: it is a sequence-resolved probe for linking peptide processing, cardiovascular biology, and emerging spike–receptor binding questions. This article outlines the mechanistic rationale, validation strategy, assay parameters, competitive landscape, and translational limits that should guide its use in hypertension and viral pathogenesis research.
-
Stable Yeast Expression of Exendin-4 for Diabetes Research
2026-08-29
The 2024 Frontiers in Systems Biology study evaluated recombinant Exendin-4 production in Escherichia coli and Saccharomyces cerevisiae, with the strongest validation obtained from a chromosomally integrated yeast strain. Detection at the expected peptide size and confirmation by immunoassay establish a foundation for investigating locally propagated production systems, while leaving purification, bioactivity, dosage, safety, and therapeutic performance for future work.